RARE | Ultragenyx Pharmaceutical Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	56.02 - 57.97
52 Week Range	31.52 - 60.37
Beta	0.06
Implied Volatility	68.15%
IV Rank	37.01%
Day's Volume	486,070
Average Volume	693,854
Shares Outstanding	92,165,200
Market Cap	5,232,218,404
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-01-31

Valuation
Profitability
Growth
Health
P/E Ratio	-7.87
Forward P/E Ratio	-6.79
EPS	-7.21
1YR Price Target	126.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1,276
Country	USA
Website	RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.

RARE's peers: AADI, ADCT, ALLK, ALNY, ARVN, CORT, CVAC, FOLD, HALO, INCY, INSM, JAZZ, MRVI, PBYI, XFOR, TERN, DAWN, PDSB, INZY, MRTX, AMLX, APLS, CRNX, RVMD, KURA, ABOS, UTHR, REGN

*Chart delayed

Analyzing fundamentals for RARE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see RARE Fundamentals page.

Watching at RARE technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RARE Technicals page.